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Rationale: Benefits of identifying risk factors for bronchopulmonary
dysplasia in extremely premature infants include providing prog-
nostic information, identifying infants likely to benefit from pre-
ventive strategies, and stratifying infants for clinical trial enrollment.
Objectives: To identify risk factors for bronchopulmonary dysplasia,
and the competing outcome of death, by postnatal day; to identify
which risk factors improve prediction; and to develop a Web-based
estimator using readily available clinical information to predict risk
of bronchopulmonary dysplasia or death.
Methods: We assessed infants of 23–30 weeks’ gestation born in 17
centers of the Eunice Kennedy Shriver National Institute of Child
Health and Human Development Neonatal Research Network and
enrolled in the Neonatal Research Network Benchmarking Trial from
2000–2004.
Measurements and Main Results: Bronchopulmonary dysplasia was
defined as a categorical variable (none, mild, moderate, or
severe). We developed and validated models for bronchopulmo-
nary dysplasia risk at six postnatal ages using gestational age, birth
weight, race and ethnicity, sex, respiratory support, and FIO2, and
examined the models using a C statistic (area under the curve).
A total of 3,636 infants were eligible for this study. Prediction
improved with advancing postnatal age, increasing from a C
statistic of 0.793 on Day 1 to a maximum of 0.854 on Day 28. On
Postnatal Days 1 and 3, gestational age best improved outcome
prediction; on Postnatal Days 7, 14, 21, and 28, type of respiratory
support did so. A Web-based model providing predicted estimates
for bronchopulmonary dysplasia by postnatal day is available at
https://neonatal.rti.org.
Conclusions: The probability of bronchopulmonary dysplasia in
extremely premature infants can be determined accurately using
a limited amount of readily available clinical information.
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AT A GLANCE COMMENTARY
Scientific Knowledge on the Subject
Bronchopulmonary dysplasia is the most common se-
rious pulmonary morbidity in premature infants. Al-
though accurate predictive models of bronchopulmonary
dysplasia risk are sometimes used in research, none are
currently used in common clinical practice for a variety
of reasons.
What This Study Adds to the Field
In this study, we identified the change in the relative
contributions of a variety of risk factors to the prediction
of bronchopulmonary dysplasia with advancing postnatal
age. This tool may help identify patients most likely to
benefit from postnatal treatment and assist in the design of
clinical trials to assess the efficacy of preventive therapies
in high-risk populations.
(Received in original form January 11, 2011; accepted in final form March 4, 2011)
Supported by The National Institutes of Health and the Eunice Kennedy Shriver
National Institute of Child Health and Human Development, which provided
grant support for the Neonatal Research Network’s Benchmarking Study (clinical
trial registered with www.clinicaltrials.gov [NCT67613] and Surfactant Positive
Airway Pressure and Pulse Oximetry Trial in Extremely Low Birth Weight Infants
(SUPPORT) (clinical trial registered with www.clinicaltrials.gov [NCT233324]).
The funding agency provided overall oversight for study conduct. All analyses
and interpretation of the data and the preparation, review, and approval of
this manuscript were independent of the funding agency. Dr. Smith received
support from the National Institute of Child Health and Human Development
(1K23HD060040–01 and DHHS-1R18AE000028–01). Data collected at partici-
pating sites of the National Institute of Child Health and Human Development
Neonatal Research Network were transmitted to RTI International, the data
coordinating center (DCC) for the network, which stored, managed, and
analyzed the data for this study. On behalf of the Neonatal Research Network,
Dr. Abhik Das (DCC principal investigator), Mr. John Langer, and Dr. Marie Gantz
(DCC statisticians) had full access to all the data in the study and take
responsibility for the integrity of the data and accuracy of the data analysis.
Correspondence and requests for reprints should be addressed to Matthew M.
Laughon, M.D., M.P.H., Division of Neonatal-Perinatal Medicine, Department
of Pediatrics, University of North Carolina at Chapel Hill, 101 Manning Drive,
CB# 7596, 4th Floor, UNC Hospitals, Chapel Hill, NC 27599–7596; E-mail: matt_
laughon@med.unc.edu
This article has an online supplement, which is accessible from this issue’s table of
contents at www.atsjournals.org
Am J Respir Crit Care Med Vol 183. pp 1715–1722, 2011
Originally Published in Press as DOI: 10.1164/rccm.201101-0055OC on March 4, 2011
Internet address: www.atsjournals.org
Bronchopulmonary dysplasia (BPD) is the most common
serious pulmonary morbidity in premature infants (1, 2). The
costs of the disorder are both social and economic and are
measured in impaired childhood health and quality of life (3),
family stress and economic hardship, and increased healthcare
costs (4). Clinicians, parents, and researchers would benefit
from an accurate predictive model of BPD risk based on readily
available clinical information. Previous predictive models of
BPD risk have been reported (5–14). Although sometimes used
in research (15), none are currently used in common clinical
practice for a variety of reasons (e.g., the populations were from
the presurfactant era or before widespread use of antenatal
steroids, BPD was defined as a dichotomous variable at a post-
natal age of limited relevance [28 d], or death was not included
in all models as a competing outcome for BPD).
An additional problem with previously reported analyses is
a lack of detail regarding the change in BPD risk with advancing
postnatal age (5–14). Traditionally, researchers identified risk
factors for BPD by categorizing premature infants as having or
not having BPD at 28 postnatal days or 36 weeks postmenstrual
age, and then examining all factors that influenced risk up to the
time of diagnosis. Subsequent multivariable models included
risk factors identifiable at birth, and exposures up to the time of
diagnosis of BPD. Using this approach, risk factors for BPD
include lower birth weight, lower gestational age, male sex,
patent ductus arteriosus (PDA), sepsis, and mechanical venti-
lation, among many others (16–19). These models typically do
not include postnatal age and therefore cannot quantify the
variable contribution of neonatal exposures over time. Includ-
ing postnatal age facilitates the development and evaluation of
potentially time-sensitive preventive or therapeutic strategies to
modify BPD risk.
Our objectives were to identify risk factors for BPD (defined
according to the National Institute of Child Health and Human
Development consensus definition of no, mild, moderate, and
severe BPD [20, 21]) and the competing outcome of death, by
postnatal day; to identify which risk factors improve prediction;
and to develop a Web-based ‘‘BPD estimator’’ using readily
available clinical information that accurately predicts the risk of
BPD or death. Some of the results of these studies have been
previously reported in the form of abstracts at the Pediatric
Academic Societies Meetings (22–24).
METHODS
Eligibility Criteria
We performed a secondary analysis of data from the Eunice Kennedy
Shriver National Institute of Child Health and Human Development
Neonatal Research Network Benchmarking Trial. This study enrolled
infants from 17 centers admitted from 2000–2004 in a cluster-random-
ized, controlled trial to test whether neonatal intensive care units
trained in benchmarking and multimodal quality improvement tech-
niques could improve survival without BPD compared with centers
with usual practice (25). All sites’ institutional review boards approved
the study. To be eligible for the Benchmarking Trial, infants needed to
survive more than 12 hours and have a birth weight of 401–1,250 g. For
this secondary analysis, infants less than 23 weeks of age were not
included because they all developed BPD, and infants greater than 30
weeks of age were not included because less than 1% of these infants
developed BPD.
Risk Factors
In the Benchmarking Trial, trained research coordinators using stan-
dardized definitions collected data before discharge, including gesta-
tional age, birth weight, race and ethnicity, and sex at birth; respiratory
support and FIO2 were recorded on specified postnatal days (26).
Gestational age (completed weeks of age) was determined by the best
obstetric estimate using the last menstrual period or early ultrasono-
graphic examination, except in unusual circumstances when only an
estimate by the pediatrician (27) was available.
Race and ethnic group were assigned by maternal report. The FIO2
and respiratory support were recorded every 6 hours starting at 0600
hour on each of the Postnatal Days 1, 3, and 7, and then once on Days
14, 21, and 28. Mean FIO2 was used on Days 1, 3, and 7 when more than
one FIO2 was recorded. We assigned the respiratory support as none,
nasal cannula, nasal continuous positive airway pressure (NCPAP),
conventional mechanical ventilation (either synchronized or non-
synchronized intermittent mandatory ventilation), or high-frequency
ventilation every 6 hours on Days 1, 3, 7, 14, 21, and 28. Infants who
never received mechanical ventilation (i.e., NCPAP only) were in-
cluded in the data. If an infant had more than one respiratory support
recorded, we used the ‘‘highest’’ form of ventilation for that day (e.g., if
an infant received both conventional mechanical ventilation and
NCPAP, the infant was coded as having received conventional
mechanical ventilation on that day). Five infants who received oxygen
via hood were included in the nasal cannula group. We did not assess
the type (e.g., continuous flow vs. variable flow) or manufacturer of any
positive–pressure device, including mechanical or high-frequency ven-
tilation. The nasal cannula flow rate was not recorded.
We examined the use of postnatal corticosteroids (15) and the
diagnoses of necrotizing enterocolitis (NEC) (28, 29) and sepsis (30),
and therapy for PDA (31) by postnatal day using standardized Neo-
natal Research Network definitions. The date of surgical ligation of the
PDA was unavailable.
Definition of BPD
BPD was defined as a categorical variable (none, mild, moderate, or
severe) among survivors by modifying the National Institutes of Health
consensus definition of BPD (20, 21) to include infants transferred
before 36 weeks and by defining the need for oxygen at 36 weeks using
a physiologic challenge (32). BPD was defined as follows: no BPD as
not receiving supplemental oxygen (O2) for 28 days or at 36 weeks;
mild BPD as receiving O2 for greater than or equal to 28 days but not
at 36 weeks; moderate BPD as receiving O2 for greater than or equal to
28 days plus treatment with less than 30% O2 at 36 weeks; and severe
BPD as receiving O2 for greater than or equal to 28 days plus greater
than or equal to 30% O2 or positive pressure at 36 weeks. For infants
transferred between 28 days and 36 weeks, we defined BPD using the
O2 therapy at the time of transfer. For infants who were discharged or
transferred less than 28 postnatal days for whom 28-day data were
unavailable, we defined no BPD as not receiving O2, mild BPD as
receiving FIO2 0.21–0.30, moderate BPD as receiving FIO2 0.31–0.5, and
severe BPD as FIO2 greater than 0.5 at the time of transfer.
Statistical Methods
A set of a priori risk factors was considered for inclusion in each
postnatal day model based on their known association with the
outcomes of BPD or death and availability in clinical records. Those
selected for potential inclusion in the models included gestational age,
birth weight, race and ethnicity, sex, respiratory support, FIO2, treat-
ment for PDA, sepsis, NEC, postnatal corticosteroids, and center (16–
19). We examined each risk factor in each category of BPD or death,
first using unadjusted analysis and then in multivariable analysis.
A series of multinomial logistic regressions were performed using
SAS software version 9.2 (SAS Institute Inc., Cary, NC), simulta-
neously modeling level of BPD or death as a function of the previously
mentioned risk factors to develop predictive models for severity of
BPD or death. Models were developed separately for each of six time
periods: Postnatal Days 1 (day of birth), 3, 7, 14, 21, and 28. Infants
were included in the model if they survived through the day of
prediction (e.g., infants in the Postnatal Day 7 model had to survive
to that day).
Final model selection was based less on statistical significance and
more on how a predictor enhanced the predictive ability of the model.
Each covariate was entered into the model using stepwise forward
selection. Six risk factors were included in the final model: (1)
gestational age, (2) birth weight, (3) race and ethnicity, (4) sex, (5)
respiratory support, and (6) FIO2. Other variables, such as sepsis, NEC
(either medical or surgical), treatment for PDA (a substitute for
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diagnosis of PDA because this variable was not in the dataset), and
postnatal corticosteroids, did not enhance the predictive ability of the
models beyond that achieved by the previously mentioned six factors
and thus were not further evaluated. Because of the need to develop
a predictive model that can be widely used, we could not include
clinical center as a factor in the models. We tested for the effect of
adding center to the models and found that the predictive ability of the
models increased only marginally: the C statistic increased by 0.9%–
1.3% for models that included center.
Predictive performance of our models was assessed using a C
statistic, which corresponds to the area under the receiver–operating
characteristic curve, which is suitable for multinomial outcomes, such
as our five-level outcome. Internal validation was accomplished by
dividing the cohort into two parts: two-thirds of the infants were
randomly selected from each site as the model development cohort,
and the remaining third were used as an internal model validation
cohort. External validation was accomplished by applying the de-
velopment models on two different cohorts of infants and comparing
the results. One cohort included infants in the recently reported
Neonatal Research Network Surfactant Positive Airway Pressure and
Pulse Oximetry Trial in Extremely Low-birth-weight Infants (SUP-
PORT) trial who were at the same centers as the Benchmarking Trial,
and the other cohort included infants in the Benchmarking Trial who
were at the same gestational age and center as those in SUPPORT
(33, 34).
RESULTS
We identified 4,095 infants with Benchmarking Trial data: 3,636
(88.8%) infants were eligible for this study; 68 infants were
excluded because of death at less than or equal to 12 hours. Ten
infants at less than 23 weeks (100% developed BPD) and 381
infants at more than 30 weeks gestation (,1% developed BPD)
were also excluded. There were seven infants for whom an
outcome was not determined.
The mean birth weight for the cohort was 897 6 203 g, the
mean gestational age was 26.7 6 1.9 weeks, the mean maternal
age was 27.2 6 6.5 years, 51% were male, and 13% received
postnatal corticosteroids (Table 1). In addition, 85% received
antenatal steroids, and 81% received surfactant.
When examining categories of BPD, increasing severity of
BPD was inversely proportional to gestational age and birth
weight (Table 1). As the severity of BPD increased, the
percentage of male infants increased. Infants with increasing
severity of BPD were also more likely to have other morbidities
of prematurity, such as PDA, sepsis, and surgical NEC (Table
1). A higher proportion of infants receiving mechanical venti-
lation, either conventional or high-frequency, compared with
NCPAP, nasal cannula, or no support at each postnatal day
developed severe BPD (Table 2). At each time point studied,
FIO2 was higher with increasing severity of BPD and death. We
present the adjusted odds ratios for each of the risk factors by
postnatal day for all outcomes in Appendix 1.
The six covariates in the final models were (1) gestational
age; (2) birth weight; (3) race and ethnicity; (4) sex; (5)
respiratory support (none, nasal cannula, NCPAP, conventional
mechanical ventilation, or high-frequency ventilation); and (6)
FIO2. These six covariates were independently strongly associ-
ated with outcome and collectively predicted outcome well.
Using the six risk-factor model, the C statistic for the Postnatal
Day 1 model was 0.793. Models for subsequent days had
a steadily increasing C statistic, reaching a maximum of 0.854
on Postnatal Day 28 (Table 3). The factor that contributed most
to model prediction changed depending on the postnatal day
(Table 3). Gestational age best improved prediction of the
outcome on Postnatal Days 1 (C statistic 5 0.750) and 3 (C
statistic 5 0.745). On Postnatal Days 7, 14, 21, and 28, type of
respiratory support increasingly improved outcome prediction
(from a C statistic of 0.771–0.823) more than any of the other
factors.
C statistics derived by fitting these models to the internal
validation cohort were similar (Table 4). In addition, we
identified 1,055 infants in the Benchmarking Trial and 722
infants in SUPPORT between 23 and 27 weeks’ gestation and at
the same centers. We applied the Postnatal Day 1, 3, 7, and 14
development models to both cohorts of infants and found that
the C statistic was always within 2% (Table 4). FIO2 data after
Day 14 were unavailable in SUPPORT.
Estimator
A prediction tool was developed that provides individual
predicted estimates of BPD risk or death at each of six postnatal
days. The model requires birth weight, gestational age, sex, race
and ethnicity, respiratory support, and FIO2 as inputs. Table 5
presents two examples of BPD risk or death for two hypothet-
ical infants. A Web-based version of this tool is available at
https://neonatal.rti.org/.
DISCUSSION
Our large, multicenter study identified the change in the
relative contributions of a variety of risk factors to the pre-
diction of BPD with advancing postnatal age. This knowledge
is important because the benefits of postnatal treatment
strategies might depend on baseline BPD risk. For example,
TABLE 1. RISK FACTORS OF STUDY POPULATION, INCLUDING OVERALL AND BY OUTCOME
No BPD Mild BPD Moderate BPD Severe BPD Death All
Number of subjects with outcome 1,218 757 714 472 468 3,629
Birth weight, g, mean 6 SD 1,042 6 149 891 6 174 839 6 180 788 6 177 727 6 173 897 6 203
Gestational age, wks, mean 6 SD 28.2 6 1.4 26.4 6 1.4 26.2 6 1.6 25.8 6 1.7 25.1 6 1.7 26.7 6 1.9
Male, % 44.2 49.4 55.9 58.9 56.4 51.1
Race: black not Hispanic, % 42.5 38.3 34.5 38.6 45.1 39.9
Ethnicity: Hispanic, % 18.1 18.8 15.4 15.7 18 17.4
Patent ductus arteriosus, n (%) 301 (25) 346 (46) 388 (54) 278 (59) 230 (49) 1,543 (43)
Indomethacin, n (%) 228 (19) 296 (39) 330 (46) 228 (48) 172 (37) 1,254 (35)
Ligation, n (%) 22 (2) 73 (10) 146 (20) 141 (30) 37 (8) 419 (12)
Early onset sepsis < 72 h, n (%) 13 (1) 14 (2) 13 (2) 10 (2) 25 (5) 75 (2)
Late-onset sepsis .72 h, n (%) 211 (17) 243 (32) 276 (39) 270 (57) 164 (35) 1,164 (32)
Necrotizing enterocolitis
Medical, n (%) 46 (4) 49 (6) 29 (4) 33 (7) 18 (4) 175 (5)
Surgical, n (%) 19 (2) 25 (3) 20 (3) 35 (7) 73 (16) 172 (5)
Postnatal corticosteroids, n (%) 9 (1) 62 (8) 154 (22) 222 (47) 32 (7) 479 (13)
Definitions of abbreviations: BPD 5 bronchopulmonary dysplasia; SD 5 standard deviation.
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the benefits of postnatal steroids for the prevention of BPD
seem to outweigh the risks only in populations of premature
infants at high risk of BPD. A meta-regression analysis of
randomized, controlled trials of BPD demonstrated that, as
the BPD risk increased above 65% in the control groups,
postnatal steroid use was associated with a decrease in the risk
of mortality or cerebral palsy; at lower baseline risk, treatment
was associated with increased risk of mortality or cerebral
TABLE 2. RESPIRATORY SUPPORT AND MEAN FIO2 FOR EACH OUTCOME BY POSTNATAL DAY (ROW PERCENTS)
Day Respiratory Support No BPD Mild BPD Moderate BPD Severe BPD Death
Maximum N 5 1,218 Maximum N 5 757 Maximum N 5 714 Maximum N 5 472 Maximum N 5 468
1 HFV, % 6 16 22 17 39
CMV, % 27 23 22 15 13
NCPAP, % 63 15 11 7 4
Nasal cannula, % 74 18 5 3 0
No ventilation, % 85 8 3 0 5
Mean FIO2, % 38 39 42 46 53
3 HFV, % 7 19 24 19 31
CMV, % 16 25 28 18 14
NCPAP, % 53 20 14 9 4
Nasal cannula, % 63 22 8 4 3
No ventilation, % 87 6 3 2 3
Mean FIO2, % 35 37 37 38 47
7 HFV, % 1 14 31 24 31
CMV, % 7 25 31 24 13
NCPAP, % 37 28 21 10 5
Nasal cannula, % 56 24 12 6 2
No ventilation, % 86 7 4 1 2
Mean FIO2, % 41 37 36 37 44
14 HFV, % 1 11 30 33 26
CMV, % 5 25 34 27 10
NCPAP, % 27 33 24 13 3
Nasal cannula, % 47 32 17 3 2
No ventilation, % 93 3 2 2 2
Mean FIO2, % 44 42 43 46 54
21 HFV, % 1 12 33 34 20
CMV, % 5 23 36 29 9
NCPAP, % 22 37 26 13 2
Nasal cannula, % 43 34 17 5 2
No ventilation, % 97 1 1 1 1
Mean FIO2, % 41 42 44 47 55
28 HFV, % 1 11 31 39 19
CMV, % 4 20 37 32 7
NCPAP, % 16 37 30 16 1
Nasal cannula, % 32 41 21 5 1
No ventilation, % 97 1 1 1 1
Mean FIO2, % 36 41 44 47 54
Definitions of abbreviations: BPD 5 bronchopulmonary dysplasia; CMV 5 conventional mechanical ventilation; HFV 5 high-frequency ventilation; NCPAP 5 nasal
continuous positive airway pressure.
TABLE 3. MODEL PREDICTION C STATISTIC (AKIN TO AREA UNDER THE RECEIVER–OPERATING CHARACTERISTIC CURVE) AND
INDIVIDUAL VARIABLES FOR DAYS 1–28 MODELS FOR THE DEVELOPMENT COHORT*
Day 1 Day 3 Day 7
Variable C Statistic Variable C Statistic Variable C Statistic
Gestational age 0.750 Gestational age 0.745 Respiratory support 0.771
Birth weight 0.772 Respiratory support 0.787 Gestational age 0.806
FIO2 0.784 Birth weight 0.798 Birth weight 0.814
Respiratory support 0.790 FIO2 0.805 FIO2 0.817
Race and ethnicity 0.791 Male sex 0.807 Race and ethnicity 0.817
Male sex 0.793 Race and ethnicity 0.807 Male sex 0.818
Day 14 Day 21 Day 28
Variable C Statistic Variable C Statistic Variable C Statistic
Respiratory support 0.795 Respiratory support 0.802 Respiratory support 0.823
Birth weight 0.819 FIO2 0.831 FIO2 0.852
Gestational age 0.825 Gestational age 0.833 Birth weight 0.851
FIO2 0.826 Birth weight 0.835 Race and ethnicity 0.853
Race and ethnicity 0.826 Race and ethnicity 0.835 Gestational age 0.853
Male sex 0.827 Male sex 0.836 Male sex 0.854
* For example, on Day 7, respiratory support provides 77.1% of the predictive ability of the C statistic, with a small incremental increase in the C statistic with
additional variables to a final model C statistic of 81.8%.
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palsy (35). In infants with more severe lung disease, cortico-
steroids seemed to reduce risk of adverse neurodevelopmental
outcome (15). In addition, steroids seem to be of greatest
benefit if used after the first postnatal week (36, 37). Our
models provide a precise and objective estimate of BPD risk
at various postnatal ages, which is essential information for
conducting trials to determine if preventive therapies, such as
postnatal corticosteroids or inhaled nitric oxide, are beneficial
in high-risk populations. These models might serve as a foun-
dation for researchers to assess long-term respiratory risk
including the development of asthma, long-term pulmonary
function test status, and potential development of emphysema
in adult life.
Previously identified risk factors for BPD include birth
weight, gestational age, male sex, oxygen therapy at 24 hours,
mechanical ventilation at 48 hours, and duration of assisted
ventilation (16–19). These factors, measured in greater detail
and at different time points, were included in our model.
We added the contribution of these factors relative to each
other and their relative importance at different postnatal
ages. For example, although oxygen exposure is a risk factor,
its independent contribution to prediction of BPD risk is
TABLE 4. INTERNAL AND EXTERNAL VALIDATION OF THE PREDICTIVE MODELS










Gestational age, wk 6 SD 26.7 6 1.9 26.8 6 1.9 25.7 6 1.1 25.7 6 1.1
Birth weight, g 6 SD 894 6 203 903 6 202 830 6 175 842 6 168
Male, % 49 54 50 56
Black, % 40 40 43 46
Hispanic, % 17 18 18 6
White, % 43 42 39 48
Antenatal steroids, % 85 85 87 96
Outcome at 36 wks PMA, %
No BPD 33 34 19 21
Mild BPD 21 21 25 30
Moderate BPD 20 19 26 23
Severe BPD 13 14 19 13
Death 13 12 11 13
Models: C statistic
Day 1 0.793 0.795 0.721 0.720
Day 3 0.807 0.810 0.738 0.732
Day 7 0.818 0.823 0.744 0.736
Day 14 0.827 0.834 0.757 0.761
Day 21 0.836 0.848 N/A N/A
Day 28 0.854 0.854 N/A N/A
Definitions of abbreviations: BPD 5 bronchopulmonary dysplasia; PMA 5 postmenstrual age; SD 5 standard deviation.
* Subset of Benchmarking Trial development model subjects who have comparable birth weight, gestational age, and clinical center to the SUPPORT study subjects.
TABLE 5. TABLE OF ESTIMATED PROBABILITIES OF BRONCHOPULMONARY DYSPLASIA OR DEATH BY POSTNATAL DAY FOR TWO
HYPOTHETICAL INFANTS
25-wk gestational age, 700-g birth weight, white, male
Probability of Outcome
Day Respiratory support and FIO2 Death Severe BPD Moderate BPD Mild BPD No BPD
1 HFV and FIO2 5 50% 0.31 0.17 0.31 0.20 0.01
3 HFV and FIO2 5 100% 0.52 0.17 0.19 0.12 0.00
7 HFV and FIO2 5 100% 0.42 0.20 0.28 0.10 0.00
14 CMV and FIO2 5 50% 0.07 0.28 0.36 0.27 0.02
21 NCPAP and FIO2 5 50% 0.02 0.19 0.36 0.39 0.04
28 Nasal cannula and FIO2 5 50% 0.01 0.06 0.28 0.57 0.07
28-wk gestational age, 1,000-g birth weight, black, female
Probability of Outcome
Day Respiratory support and FIO2 Death Severe BPD Moderate BPD Mild BPD No BPD
1 CMV and FIO2 5 70% 0.06 0.09 0.15 0.23 0.47
3 CMV and FIO2 5 35% 0.05 0.09 0.22 0.30 0.34
7 Nasal cannula and FIO2 5 50% 0.01 0.04 0.09 0.21 0.65
14 No ventilation and room air 0.02 0.01 0.01 0.03 0.93
21 No ventilation and room air 0.01 0.01 0.01 0.01 0.96
28 No ventilation and room air 0.01 0.00 0.00 0.01 0.97
Definitions of abbreviations: BPD 5 bronchopulmonary dysplasia; CMV 5 conventional mechanical ventilation; HFV 5 high-frequency ventilation; NCPAP 5 nasal
continuous positive airway pressure.
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small relative to gestational age on Postnatal Day 1 and to
respiratory support thereafter. Risk factors that were found
to be significant in previous studies but that we did not
include in our final models include PDA, NEC, sepsis, and
postnatal corticosteroids (16–19). None of these factors
improved prediction of the risk of BPD after adjustment for
the six critical risk factors.
Previous BPD prediction scoring systems have been de-
scribed, but none has been widely adopted. Some have satis-
factory sensitivity and specificity but use oxygen therapy at 28
postnatal days as a definition of BPD, which is now outdated (5–
7). Some include radiographs as part of the scoring system,
which introduces subjectivity and reduces generalizability (8–
11). Other problems limiting the use of these models are the
inclusion of ventilated infants only, the lack of categorization of
BPD by severity, the exclusion of infants who die, and underuse
of antenatal corticosteroids and surfactant therapy (8–13, 38,
39). Most importantly, none examined models by postnatal day
through the first 28 postnatal days. In addition, we internally
and externally validated our models; our models were able
successfully to classify infants in the internal validation sample
into the correct level of BPD or death in more than 8 out of 10
cases. The models performed similarly in subjects in the
SUPPORT trial who were born between 2004 and 2009. The
C statistic is lower for both the subset of subjects in the reduced
Benchmarking group and SUPPORT group because the ex-
cluded subjects had higher and lower gestational ages, and
outcome is more accurately predicted at the extreme values
(i.e., subjects with higher gestational age have better outcomes,
with more accuracy; subjects with lower gestational age have
worse outcomes, again with more accuracy).
We developed an on-line application of the prediction
models. Caution should be exercised when using the on-line
estimator to identify BPD risk in populations in which the
demography or care practices differ markedly from our cohort.
Our models and the on-line application were based on data
from Level III neonatal intensive care units at large, mostly
urban academic medical centers. Because our BPD definitions
depended in part on various respiratory therapies, center-
specific use of these therapies might influence the prediction
models. For example, we speculate that high-frequency venti-
lation was most likely used in our study centers as a ‘‘rescue’’
therapy for infants with profound respiratory failure or pulmo-
nary interstitial emphysema (40), and therefore BPD risks were
higher among infants exposed to high-frequency ventilation. In
centers where high-frequency ventilation is used as a primary
therapy, BPD risk might be overestimated using our model (41).
In conclusion, we found that gestational age conveyed the
most predictive information for BPD risk on Postnatal Days 1
and 3, and respiratory support on Days 7, 14, 21, and 28. The
BPD estimator will provide prognostic information for families
and clinicians, and will assist in identifying the optimal candi-
dates for enrollment in clinical trials to prevent BPD.
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